TY - JOUR
T1 - Opportunities for Drug Repurposing of Serotonin Reuptake Inhibitors
T2 - Potential Uses in Inflammation, Infection, Cancer, Neuroprotection, and Alzheimer's Disease Prevention
AU - Nykamp, Madeline J.
AU - Zorumski, Charles F.
AU - Reiersen, Angela M.
AU - Nicol, Ginger E.
AU - Cirrito, John
AU - Lenze, Eric J.
N1 - Publisher Copyright:
© 2021 Hogrefe Publishing GmbH. All rights reserved.
PY - 2021
Y1 - 2021
N2 - Serotonin reuptake inhibitors (SRIs) are safe and widely used for a variety of indications including depressive disorders, anxiety, and chronic pain. Besides inhibiting the serotonin transporter, these medications have broad-spectrum properties in many systems. Their roles have been studied in cancer, Alzheimer's disease, and infectious processes. The COVID-19 pandemic highlighted the importance of drug repurposing of medications already in use. We conducted a narrative review of current evidence and ongoing research on drug repurposing of SRIs, with a focus on immunomodulatory, antiproliferative, and neuroprotective activity. SRIs may have clinical use as repurposed agents for a wide variety of conditions including but not limited to COVID-19, Alzheimer's disease, and neoplastic processes. Further research, particularly randomized controlled trials, will be necessary to confirm the utility of SRIs for new indications.
AB - Serotonin reuptake inhibitors (SRIs) are safe and widely used for a variety of indications including depressive disorders, anxiety, and chronic pain. Besides inhibiting the serotonin transporter, these medications have broad-spectrum properties in many systems. Their roles have been studied in cancer, Alzheimer's disease, and infectious processes. The COVID-19 pandemic highlighted the importance of drug repurposing of medications already in use. We conducted a narrative review of current evidence and ongoing research on drug repurposing of SRIs, with a focus on immunomodulatory, antiproliferative, and neuroprotective activity. SRIs may have clinical use as repurposed agents for a wide variety of conditions including but not limited to COVID-19, Alzheimer's disease, and neoplastic processes. Further research, particularly randomized controlled trials, will be necessary to confirm the utility of SRIs for new indications.
KW - Alzheimer-s disease (AD)
KW - Antiinflammatory agents
KW - COVID 19
KW - Drug Repurposing
KW - Selective serotonin reuptake inhibitors (SSRIs)
UR - http://www.scopus.com/inward/record.url?scp=85121322245&partnerID=8YFLogxK
U2 - 10.1055/a-1686-9620
DO - 10.1055/a-1686-9620
M3 - Review article
C2 - 34875696
AN - SCOPUS:85121322245
SN - 0176-3679
JO - Pharmacopsychiatry
JF - Pharmacopsychiatry
ER -